Clinical Trial

CluePoints Sponsored RBQMLive Returns for 2025

Expert Speaker Lineup announced for leading RBQM event KING OF PRUSSIA, Pa., Sept. 23, 2025 /PRNewswire/ -- CluePoints, the premier…

3 months ago

Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously

Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's…

3 months ago

Inato and RealTime eClinical Solutions Partner to Deliver Unparalleled Site Performance and Patient Access Data to Sponsors

NEW YORK and SAN ANTONIO, Sept. 23, 2025 /PRNewswire/ -- Today, Inato and RealTime eClinical Solutions announced a partnership to enhance…

3 months ago

PathAI Launches Industry-Backed AIM-HI UC Model on GCP-Compliant Platform to Standardize Histological Assessment in Ulcerative Colitis Trials

BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- PathAI, the global leader in AI-powered pathology, today announced the integration of AIM-HI…

3 months ago

PridCor Therapeutics Principal Investigator Dr. David Putrino Participates in National Long COVID Roundtable Convened by Secretary Robert F. Kennedy Jr.

HHS Advances Fight Against Long COVID with Patient Roundtables and New National Efforts TUSCALOOSA, Ala., Sept. 23, 2025 (GLOBE NEWSWIRE)…

3 months ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlights emerging…

3 months ago

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa

HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued…

3 months ago

Aphaia Pharma Publishes Phase 1 and 2 Clinical Data of Oral Formulation in Patients with Obesity and Prediabetes

Aphaia’s lead formulation orchestrates a comprehensive hormonal response from nutrient-sensing cells with potential to modify the course of obesity and…

3 months ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for…

3 months ago